Immunologic Basis of Type 2 Biologics for Severe Asthma

키워드

참고문헌 (101)

1. Kaur R, "Phenotypes and endotypes of adult asthma : moving toward precision medicine", J Allergy Clin Immunol, 144, pp.1~12 (2019)
2. Asher I, "Calling time on asthma deaths in tropical regions-how much longer must people wait for essential medicines?", Lancet Respir Med, 7, pp.13~15 (2019)
3. Reddel HK, "Global Initiative for Asthma strategy 2021 : executive summary and rationale for key changes", Eur Respir J, 59, pp.2102730~ (2021)
4. Holguin F, "Management of severe asthma : a European Respiratory Society", American Thoracic Society guideline, 2020, pp.55, 1900588~
5. Busse WW, "Current unmet needs and potential solutions to uncontrolled asthma", Eur Respir Rev, 31, pp.210176~ (2022)
6. McGregor MC, "Role of biologics in asthma", Am J Respir Crit Care Med, 199, pp.433~445 (2019)
7. Moore WC, "Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program", J Allergy Clin Immunol, 119, pp.405~413 (2007)
8. Wenzel SE, "Asthma phenotypes : the evolution from clinical to molecular approaches", Nat Med, 18, pp.716~725 (2012)
9. WoodruffPG, "T-helper type 2-driven inflammation defines major subphenotypes of asthma", Am J Respir Crit Care Med, 180, pp.388~395 (2009)
10. Fahy JV, "Type 2 inflammation in asthma--present in most, absent in many", Nat Rev Immunol, 15, pp.57~65 (2015)
11. Israel E, "Severe and difficult-to-treat asthma in adults", N Engl J Med, 377, pp.965~976 (2017)
12. Youngwoo Choi, "Distinct functions of eosinophils in severe asthma with type 2 phenotype: clinical implications", The Korean Journal of Internal Medicine, 35(4), pp.823~833 (2020), 대한내과학회[DOI]
13. Sim S, "Potential metabolic biomarkers in adult asthmatics", Metabolites, 11, pp.430~ (2021)
14. 이영수, "Serum Levels of Eosinophil-Derived Neurotoxin: A Biomarker for Asthma Severity in Adult Asthmatics", Allergy, Asthma & Immunology Research, 11(3), pp.394~405 (2019), 대한천식알레르기학회
15. 최영우, "Biological function of eosinophil extracellular traps in patients with severe eosinophilic asthma", Experimental and Molecular Medicine, 50, pp.1~8 (2018), 생화학분자생물학회
16. Choi Y, "Eosinophil extracellular traps activate type 2 innate lymphoid cells through stimulating airway epithelium in severe asthma", Allergy, 75, pp.95~103 (2020)
17. Kim HJ, "Lysophosphatidylserine induces eosinophil extracellular trap formation and degranulation : Implications in severe asthma", Allergy, 75, pp.3159~3170 (2020)
18. Rodriguez-Rodriguez N, "Group 2 innate lymphoid cells : team players in regulating asthma", Annu Rev Immunol, 39, pp.167~198 (2021)
19. Trinh HK, "Epithelial folliculin enhances airway inflammation in aspirin-exacerbated respiratory disease", Clin Exp Allergy, 48, pp.1464~1473 (2018)
20. Choi Y, "Immunomodulatory function of surfactant protein D in eosinophilic asthma", Allergy, 74, pp.192~195 (2019)
21. Choi Y, "Surfactant protein D alleviates eosinophil-mediated airway inflammation and remodeling in patients with aspirin-exacerbated respiratory disease", Allergy, 74, pp.78~88 (2019)
22. 최영우, "Which Factors Associated With Activated Eosinophils Contribute to the Pathogenesis of Aspirin-Exacerbated Respiratory Disease?", Allergy, Asthma & Immunology Research, 11(3), pp.320~329 (2019), 대한천식알레르기학회
23. Choi Y, "Pulmonary surfactants : a new therapeutic target in asthma", Curr Allergy Asthma Rep, 20, pp.70~ (2020)
24. Sim S, "Contribution of dipeptidyl peptidase 10 to airway dysfunction in patients with NSAID-exacerbated respiratory disease", Clin Exp Allergy, 52, pp.115~126 (2022)
25. Park H, "Potential biomarkers for NSAID-exacerbated respiratory disease", Mediators Inflamm, 2017, pp.8160148~ (2017)
26. Hudey SN, "Mechanisms of non-type 2 asthma", Curr Opin Immunol, 66, pp.123~128 (2020)
27. Esteban-Gorgojo I, "Non-eosinophilic asthma : current perspectives", J Asthma Allergy, 11, pp.267~281 (2018)
28. Kim YM, "Airway G-CSF identifies neutrophilic inflammation and contributes to asthma progression", Eur Respir J, 55, pp.1900827~ (2020)
29. Choi Y, "Neutrophil activation in occupational asthma", Curr Opin Allergy Clin Immunol, 19, pp.81~85 (2019)
30. Choi Y, "Neutrophil extracellular DNA traps induce autoantigen production by airway epithelial cells", Mediators Inflamm, 2017, pp.5675029~ (2017)
31. Quang Luu Quoc, "S100A9 in adult asthmatic patients: a biomarker for neutrophilic asthma", Experimental and Molecular Medicine, 53, pp.1~10 (2021), 생화학분자생물학회[DOI]
32. Bich Tra Cao Thi, "Serum Amyloid A1: A Biomarker for Neutrophilic Airway Inflammation in Adult Asthmatic Patients", Allergy, Asthma & Immunology Research, 14(1), pp.40~58 (2022), 대한천식알레르기학회[DOI]
33. Marone G, "Role of human mast cells and basophils in bronchial asthma", Adv Immunol, 88, pp.97~160 (2005)
34. Marone G, "Mast cells and basophils : friends as well as foes in bronchial asthma?", Trends Immunol, 26, pp.25~31 (2005)
35. Gelfand EW, "Role of histamine in the pathophysiology of asthma : immunomodulatory and antiinflammatory activities of H1-receptor antagonists", Am J Med, 113(Suppl 9A), pp.2~ (2002)
36. Hart PH, "Regulation of the inflammatory response in asthma by mast cell products", Immunol Cell Biol, 79, pp.149~153 (2001)
37. Saluja R, "The role of the IL-33", IL-1RL1 axis in mast cell and basophil activation in allergic disorders, 2015, pp.63, 80~85
38. Kubo M, "Mast cells and basophils in allergic inflammation", Curr Opin Immunol, 54, pp.74~79 (2018)
39. Denlinger LC, "Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations", Am J Respir Crit Care Med, 195, pp.302~313 (2017)
40. Weller PF, "Human eosinophils", J Allergy Clin Immunol, 100, pp.283~287 (1997)
41. Kita H, "Release of granule proteins from eosinophils cultured with IL-5", J Immunol, 149, pp.629~635 (1992)
42. Acharya KR, "Eosinophil granule proteins : form and function", J Biol Chem, 289, pp.17406~17415 (2014)
43. Lee Youngsoo, "Biomarkers for Severe Asthma: Lessons From Longitudinal Cohort Studies", Allergy, Asthma & Immunology Research, 13(3), pp.375~389 (2021), 대한천식알레르기학회[DOI]
44. 허규영, "Clinical Characteristics of NSAID-induced Blended Reaction", Allergy, Asthma & Immunology Research, 13(2), pp.171~172 (2021), 대한천식알레르기학회[DOI]
45. Rhyou Hyo-In, "Emerging Biomarkers Beyond Leukotrienes for the Management of Nonsteroidal Anti-inflammatory Drug (NSAID)-Exacerbated Respiratory Disease", Allergy, Asthma & Immunology Research, 14(2), pp.153~167 (2022), 대한천식알레르기학회[DOI]
46. Yokomizo T, "Leukotriene receptors as potential therapeutic targets", J Clin Invest, 128, pp.2691~2701 (2018)
47. Rosales C, "Neutrophil : a cell with many roles in inflammation or several cell types?", Front Physiol, 9, pp.113~ (2018)
48. Ray A, "Neutrophilic inflammation in asthma and association with disease severity", Trends Immunol, 38, pp.942~954 (2017)
49. Crisford H, "Neutrophils in asthma : the good, the bad and the bacteria", Thorax, 76, pp.835~844 (2021)
50. Ventura I, "Neutrophils from allergic asthmatic patients produce and release metalloproteinase-9 upon direct exposure to allergens", Allergy, 69, pp.898~905 (2014)
51. Mattos W, "Matrix metalloproteinase-9 expression in asthma : effect of asthma severity, allergen challenge, and inhaled corticosteroids", Chest, 122, pp.1543~1552 (2002)
52. Brinkmann V, "Neutrophil extracellular traps kill bacteria", Science, 303, pp.1532~1535 (2004)
53. Vargas A, "Neutrophil extracellular traps are downregulated by glucocorticosteroids in lungs in an equine model of asthma", Respir Res, 18, pp.207~ (2017)
54. Grabcanovic-Musija F, "Neutrophil extracellular trap(NET)formation characterises stable and exacerbated COPD and correlates with airflow limitation", Respir Res, 16, pp.59~ (2015)
55. Fricker M, "Macrophage dysfunction in the pathogenesis and treatment of asthma", Eur Respir J, 50, pp.1700196~ (2017)
56. Saradna A, "Macrophage polarization and allergic asthma", Transl Res, 191, pp.1~14 (2018)
57. Benson RC, "Arginase and arginine dysregulation in asthma", J Allergy(Cairo), 2011, pp.736319~ (2011)
58. Zhu X, "The Role of T cells and macrophages in asthma pathogenesis : a new perspective on mutual crosstalk", Mediators Inflamm, 2020, pp.7835284~ (2020)
59. Lloyd CM, "Functions of T cells in asthma : more than just TH2 cells", Nat Rev Immunol, 10, pp.838~848 (2010)
60. Massey O, "Recent advances in the inhibition of the IL-4 cytokine pathway for the treatment of allergen-induced asthma", Int J Mol Sci, 22, pp.13655~ (2021)
61. Martín-Orozco E, "Regulatory T cells in allergy and asthma", Front Pediatr, 5, pp.117~ (2017)
62. Yu S, "Innate lymphoid cells and asthma", J Allergy Clin Immunol, 133, pp.943~950 (2014)
63. Zheng H, "The role of type 2 innate lymphoid cells in allergic diseases", Front Immunol, 12, pp.586078~ (2021)
64. Liu S, "Steroid resistance of airway type 2 innate lymphoid cells from patients with severe asthma : The role of thymic stromal lymphopoietin", J Allergy Clin Immunol, 141, pp.257~268 (2018)
65. Ozyigit LP, "Innate lymphocyte cells in asthma phenotypes", Clin Transl Allergy, 5, pp.23~ (2015)
66. Kim J, "Innate immune crosstalk in asthmatic airways : Innate lymphoid cells coordinate polarization of lung macrophages", J Allergy Clin Immunol, 143, pp.1769~1782 (2019)
67. Bousquet J, "Real-world effectiveness of omalizumab in severe allergic asthma : a meta-analysis of observational studies", J Allergy Clin Immunol Pract, 9, pp.2702~2714 (2021)
68. Agache I, "Efficacy and safety of treatment with biologicals(benralizumab, dupilumab and omalizumab)for severe allergic asthma : a systematic review for the EAACI guidelines-recommendations on the use of biologicals in severe asthma", Allergy, 75, pp.1043~1057 (2020)
69. Albers FC, "Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma", Respir Med, 159, pp.105806~ (2019)
70. Bel EH, "Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma", N Engl J Med, 371, pp.1189~1197 (2014)
71. Brusselle G, "Reslizumab in patients with inadequately controlled lateonset asthma and elevated blood eosinophils", Pulm Pharmacol Ther, 43, pp.39~45 (2017)
72. Farne HA, "Anti-IL5 therapies for asthma", Cochrane Database Syst Rev, 9, pp.CD010834~ (2017)
73. Bleecker ER, "Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma", Eur Respir J, 52, pp.1800936~ (2018)
74. Nair P, "Oral glucocorticoid-sparing effect of benralizumab in severe asthma", N Engl J Med, 376, pp.2448~2458 (2017)
75. Castro M, "Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma", N Engl J Med, 378, pp.2486~2496 (2018)
76. Wechsler ME, "Efficacy and safety of itepekimab in patients with moderate-to-severe asthma", N Engl J Med, 385, pp.1656~1668 (2021)
77. Kelsen SG, "Astegolimab(anti-ST2)efficacy and safety in adults with severe asthma : a randomized clinical trial", J Allergy Clin Immunol, 148, pp.790~798 (2021)
78. Corren J, "Tezepelumab in adults with uncontrolled asthma", N Engl J Med, 377, pp.936~946 (2017)
79. Menzies-Gow A, "Tezepelumab in adults and adolescents with severe, uncontrolled asthma", N Engl J Med, 384, pp.1800~1809 (2021)
80. McCracken JL, "Biologic therapy in the management of asthma", Curr Opin Allergy Clin Immunol, 16, pp.375~382 (2016)
81. Humbert M, "Omalizumab in asthma : an update on recent developments", J Allergy Clin Immunol Pract, 2, pp.525~536 (2014)
82. Manka LA, "Selecting the right biologic for your patients with severe asthma", Ann Allergy Asthma Immunol, 121, pp.406~413 (2018)
83. Casale TB, "Omalizumab effectiveness by biomarker status in patients with asthma : evidence from PROSPERO, a prospective realworld study", J Allergy Clin Immunol Pract, 7, pp.156~164 (2019)
84. Garcia G, "A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma", Chest, 144, pp.411~419 (2013)
85. Khatri S, "Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma", J Allergy Clin Immunol, 143, pp.1742~1751 (2019)
86. Menzella F, "Anti-IL5 therapies for severe eosinophilic asthma : literature review and practical insights", J Asthma Allergy, 13, pp.301~313 (2020)
87. Harvey ES, "Mepolizumab effectiveness and identification of super-responders in severe asthma", Eur Respir J, 55, pp.1902420~ (2020)
88. Corren J, "Phase 3 study of reslizumab in patients with poorly controlled asthma : effects across a broad range of eosinophil counts", Chest, 150, pp.799~810 (2016)
89. Castro M, "Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts : results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials", Lancet Respir Med, 3, pp.355~366 (2015)
90. Jang Jae-Hyuk, "Changes in Type 2 Biomarkers After Anti-IL5 Treatment in Patients With Severe Eosinophilic Asthma", Allergy, Asthma & Immunology Research, 13(2), pp.330~338 (2021), 대한천식알레르기학회[DOI]
91. Dávila González I, "Benralizumab : a new approach for the treatment of severe eosinophilic asthma", J Investig Allergol Clin Immunol, 29, pp.84~93 (2019)
92. FitzGerald JM, "Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma(CALIMA) : a randomised, doubleblind, placebo-controlled phase 3 trial", Lancet, 388, pp.2128~2141 (2016)
93. Pepper AN, "Biologic therapy and novel molecular targets of severe asthma", J Allergy Clin Immunol Pract, 5, pp.909~916 (2017)
94. Borish LC, "Efficacy of soluble IL-4 receptor for the treatment of adults with asthma", J Allergy Clin Immunol, 107, pp.963~970 (2001)
95. Corren J, "A randomized, controlled, phase 2 study of AMG 317, an IL-4Rα antagonist, in patients with asthma", Am J Respir Crit Care Med, 181, pp.788~796 (2010)
96. Hanania NA, "Efficacy and safety of lebrikizumab in patients with uncontrolled asthma(LAVOLTA I and LAVOLTA II) : replicate, phase 3, randomised, double-blind, placebo-controlled trials", Lancet Respir Med, 4, pp.781~796 (2016)
97. Panettieri RA Jr, "Tralokinumab for severe, uncontrolled asthma(STRATOS 1 and STRATOS 2) : two randomised, doubleblind, placebo-controlled, phase 3 clinical trials", Lancet Respir Med, 6, pp.511~525 (2018)
98. Marone G, "Tezepelumab : a novel biological therapy for the treatment of severe uncontrolled asthma", Expert Opin Investig Drugs, 28, pp.931~940 (2019)
99. Gauvreau G, "Late breaking abstract-efficacy of CSJ117 on allergen-induced asthmatic responses in mild atopic asthma patients", Eur Respir J, 56, pp.3690~ (2020)
100. Lee J, "Perspective from the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference", Front Med(Lausanne), 5, pp.306~ (2018)
101. Nixon J, "Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation", Pharmacol Ther, 169, pp.57~77 (2017)

관련 논문AI추천